Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 241
Filtrar
1.
Eur Spine J ; 32(3): 787-796, 2023 03.
Artículo en Inglés | MEDLINE | ID: mdl-36459201

RESUMEN

PURPOSE: Increased fatty infiltration in paraspinal muscles has been recognized as a feature of muscle quality loss in people with Low Back Pain (LBP) and is highly associated with the severity of LBP and dysfunction. Reducing fatty infiltration has been recognized as a rehabilitation aim. An earlier systematic review published in 2014 revealed conflicting evidence for the reversibility of paraspinal muscle quality by means of exercise and no updates have been published since. A new systematic literature search is warranted. METHOD: Pubmed, CINAHL and Embase were searched from inception to July 2022. Randomized, non-randomized controlled trials (RCT and non-RCT) and single-arm trials were included if they reported the effect of exercise on paraspinal fatty infiltration in people with LBP. Effect sizes and statistical power were calculated for (1) exercise versus control, and (2) pre-post exercise changes. Available data from the RCTs were pooled via meta-analysis when appropriate. Otherwise, data were synthesized qualitatively. RESULTS: Two RCTs, one non-RCT and three single-arm trials met the selection criteria. Data were not pooled due to substantial clinical heterogeneity. Effect sizes from the RCTs revealed no significant difference for exercise versus control. One single-arm trial with high risk of bias demonstrated a significant pre-post difference with moderate effect size, but only at one (T12-L1) of the investigated levels. CONCLUSION: Moderate quality evidence is available that paraspinal fatty infiltration is not reversible with exercise in people with LBP. More larger RCT's are needed to draw firmer conclusions.


Asunto(s)
Dolor de la Región Lumbar , Humanos , Ejercicio Físico , Terapia por Ejercicio , Dolor de la Región Lumbar/terapia , Músculos , Músculos Paraespinales
2.
Syst Rev ; 10(1): 309, 2021 12 07.
Artículo en Inglés | MEDLINE | ID: mdl-34876231

RESUMEN

Although systematic reviews are considered as central components in evidence-based practice, they currently face an important challenge to keep up with the exponential publication rate of clinical trials. After initial publication, only a minority of the systematic reviews are updated, and it often takes multiple years before these results become accessible. Consequently, many systematic reviews are not up to date, thereby increasing the time-gap between research findings and clinical practice. A potential solution is offered by a living systematic reviews approach. These types of studies are characterized by a workflow of continuous updates which decreases the time it takes to disseminate new findings. Although living systematic reviews are specifically designed to continuously synthesize new evidence in rapidly emerging topics, they have also considerable potential in slower developing domains, such as rehabilitation science. In this commentary, we outline the rationale and required steps to transition a regular systematic review into a living systematic review. We also propose a workflow that is designed for rehabilitation science.


Asunto(s)
Medicina Basada en la Evidencia , Práctica Clínica Basada en la Evidencia , Humanos , Revisiones Sistemáticas como Asunto
4.
Musculoskelet Sci Pract ; 45: 102072, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-31756668

RESUMEN

INTRODUCTION: Musculoskeletal pain (MSP) is a burden to patients and to society. In addition to well-known prognostic factors, illness perceptions (IPs) may be associated with pain intensity and physical functioning in MSP but their role is not fully understood. Our research focused on these questions: 1) Do IPs differ between patients with acute, sub-acute and persistent MSP 2) Are IPs, in addition to well-known prognostic factors, associated with pain intensity and with limitations in physical functioning? METHODS: Eligible MSP patients from 29 physical therapy practices were invited to participate in a cross-sectional study. IPs were measured with the Brief IPQ-DLV. We compared IPs between patients with acute, sub-acute and persistent MSP (1-way ANOVA with Tukey post-hoc tests). Secondly, associations between IPs with pain intensity and physical functioning were assessed (multiple linear regression). RESULTS: With 658 participants, most IP dimensions showed small differences between acute, sub-acute or persistent pain. For pain intensity, the IP dimensions Consequences, Identity and Comprehensibility explained an additional 13.3% of the variance. For physical functioning, the dimensions Consequences, Treatment Control, Identity and Concern explained an additional 26.5% of the variance. DISCUSSION/CONCLUSION: Most IP dimensions showed small differences between acute, sub-acute or persistent pain. In addition to some well-known prognostic variables, higher scores on some IP dimensions are associated with higher pain intensity and more limitations in physical functioning in patients with MSP. Longitudinal studies are needed to explore the longitudinal associations.


Asunto(s)
Dolor Musculoesquelético/fisiopatología , Dolor Musculoesquelético/psicología , Pacientes Ambulatorios/psicología , Dimensión del Dolor/psicología , Percepción , Modalidades de Fisioterapia/estadística & datos numéricos , Índice de Severidad de la Enfermedad , Adolescente , Adulto , Anciano , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Países Bajos , Pacientes Ambulatorios/estadística & datos numéricos , Dimensión del Dolor/estadística & datos numéricos , Encuestas y Cuestionarios , Adulto Joven
5.
Musculoskelet Sci Pract ; 48: 102090, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-31744776

RESUMEN

BACKGROUND: Previous systematic reviews revealed poor reliability and validity for sacroiliac joint (SIJ) mobility tests. However, these reviews were published nearly 20 years ago and recent evidence has not yet been summarised. OBJECTIVES: To conduct an up-to-date systematic review to verify whether recommendations regarding the clinical use of SIJ mobility tests should be revised. STUDY DESIGN: Systematic review. METHOD: The literature was searched for relevant articles via 5 electronic databases. The review was conducted according to the PRISMA guidelines. COSMIN checklists were used to appraise the methodological quality. Studies were included if they had at least fair methodology and reported clinimetric properties of SIJ mobility tests performed in adult patients with non-specific low back pain, pelvic (girdle) pain and/or SIJ pain. Only tests that can be performed in a clinical setting were considered. RESULTS: Twelve relevant articles were identified, of which three were of sufficient methodological quality. These three studies evaluated the reliability of eight SIJ mobility tests and one test cluster. For the majority of individual tests, the intertester reliability showed slight to fair agreement. Although some tests and one test cluster had higher reliability, the confidence intervals around most reliability estimates were large. Furthermore, there were no validity studies of sufficient methodological quality. CONCLUSION: Considering the low and/or imprecise reliability estimates, the absence of high-quality diagnostic accuracy studies, and the uncertainty regarding the construct these tests aim to measure, this review supports the previous recommendations that the use of SIJ mobility tests in clinical practice is problematic.


Asunto(s)
Dolor de la Región Lumbar , Articulación Sacroiliaca , Adulto , Artralgia , Dolor de Espalda , Humanos , Dolor de la Región Lumbar/diagnóstico , Reproducibilidad de los Resultados
6.
Eur J Pain ; 22(9): 1577-1596, 2018 10.
Artículo en Inglés | MEDLINE | ID: mdl-29845678

RESUMEN

Generic self-management programs aim to facilitate behavioural adjustment and therefore have considerable potential for patients with chronic musculoskeletal pain. Our main objective was to collect and synthesize all data on the effectiveness of generic self-management interventions for patients with chronic musculoskeletal pain in terms of physical function, self-efficacy, pain intensity and physical activity. Our secondary objective was to describe the content of these interventions, by means of classification according to the Behaviour Change Technique Taxonomy. We searched PubMed, CENTRAL, Embase and Psycinfo for eligible studies. Study selection, data extraction and risk of bias were assessed by two researchers independently. Meta-analyses were only performed if the studies were sufficiently homogeneous and GRADE was used to determine the quality of evidence. We identified 20 randomized controlled trials that compared a self-management intervention to any type of control group. For post-intervention results, there was moderate quality evidence of a statistically significant but clinically unimportant effect for physical function and pain intensity, both favouring the self-management group. At follow-up, there was moderate quality evidence of a small clinically insignificant effect for self-efficacy, favouring the self-management group. All other comparisons did not indicate an effect. Classification of the behaviour change techniques showed large heterogeneity across studies. These results indicate that generic self-management interventions have a marginal benefit for patients with chronic musculoskeletal pain in the short-term for physical function and pain intensity and for self-efficacy in the long-term, and vary considerably with respect to intervention content. SIGNIFICANCE: This study contributes to a growing body of evidence that generic self-management interventions have limited effectiveness for patients with chronic musculoskeletal pain. Furthermore, this study has identified substantial differences in both content and delivery mode across self-management interventions.


Asunto(s)
Dolor Crónico/terapia , Ejercicio Físico , Dolor Musculoesquelético/terapia , Autoeficacia , Automanejo , Dolor Crónico/psicología , Humanos , Dolor Musculoesquelético/psicología
7.
J Evol Biol ; 28(4): 826-40, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25704153

RESUMEN

Clines in life history traits, presumably driven by spatially varying selection, are widespread. Major latitudinal clines have been observed, for example, in Drosophila melanogaster, an ancestrally tropical insect from Africa that has colonized temperate habitats on multiple continents. Yet, how geographic factors other than latitude, such as altitude or longitude, affect life history in this species remains poorly understood. Moreover, most previous work has been performed on derived European, American and Australian populations, but whether life history also varies predictably with geography in the ancestral Afro-tropical range has not been investigated systematically. Here, we have examined life history variation among populations of D. melanogaster from sub-Saharan Africa. Viability and reproductive diapause did not vary with geography, but body size increased with altitude, latitude and longitude. Early fecundity covaried positively with altitude and latitude, whereas lifespan showed the opposite trend. Examination of genetic variance-covariance matrices revealed geographic differentiation also in trade-off structure, and QST -FST analysis showed that life history differentiation among populations is likely shaped by selection. Together, our results suggest that geographic and/or climatic factors drive adaptive phenotypic differentiation among ancestral African populations and confirm the widely held notion that latitude and altitude represent parallel gradients.


Asunto(s)
Drosophila melanogaster/fisiología , Variación Genética , Genética de Población , Selección Genética , África del Sur del Sahara , Altitud , Animales , Tamaño Corporal/genética , Femenino , Fertilidad/genética
8.
Meat Sci ; 97(4): 558-67, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24769877

RESUMEN

This study was designed to provide updated information on the separable components, cooking yields, and proximate composition of retail cuts from the beef chuck. Additionally, the impact the United States Department of Agriculture (USDA) Quality and Yield Grade may have on such factors was investigated. Ultimately, these data will be used in the USDA - Nutrient Data Laboratory's (NDL) National Nutrient Database for Standard Reference (SR). To represent the current United States beef supply, seventy-two carcasses were selected from six regions of the country based on USDA Yield Grade, USDA Quality Grade, gender, and genetic type. Whole beef chuck primals from selected carcasses were shipped to three university laboratories for subsequent retail cut fabrication, raw and cooked cut dissection, and proximate analyses. The incorporation of these data into the SR will improve dietary education, product labeling, and other applications both domestically and abroad, thus emphasizing the importance of accurate and relevant beef nutrient data.


Asunto(s)
Comercio , Culinaria , Bases de Datos Factuales , Dieta , Carne/análisis , Valor Nutritivo , United States Department of Agriculture , Animales , Bovinos , Femenino , Humanos , Masculino , Carne/clasificación , Estándares de Referencia , Estados Unidos
9.
Br J Sports Med ; 43(9): 722-5, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19734508

RESUMEN

BACKGROUND: In spite of the benefits of physical activity, exercise may provoke acute cardiac events in susceptible individuals. Understanding risk factors of exercise-related acute cardiac events may identify opportunities for prevention. METHODS: A case-control study was conducted to examine determinants of acute cardiac events in athletes. The cases were athletes who suffered an acute cardiac event during or shortly after vigorous exercise. Athletes who visited a hospital because of a minor sports injury were selected as controls. Information on cardiovascular disease, family history of cardiovascular disease, cardiovascular symptoms and other potential risk factors was collected through questionnaires. RESULTS: 57 cases (mean age 41.8 years, range 11-73) and 57 controls (mean age 40.9 years, range 13-68) were included in the study. Athletes with a history of cardiovascular disease were at a markedly increased risk for cardiac events during exercise (OR = 32; 95% CI 7.4 to 143). Smoking (OR 5.9; 95% CI 1.9 to 18), fatigue (OR = 12; 95% CI 1.2 to 118) and flu-like symptoms (OR 13; 95% CI 1.4 to 131) in the month preceding the event were related to acute cardiac events in athletes. CONCLUSIONS: Prior cardiovascular disease, smoking, and a recent episode of fatigue or flu-like symptoms are associated with an increased risk of exercise-related acute cardiac events. Athletes and physicians should pay careful attention when these factors exist or occur.


Asunto(s)
Enfermedades Cardiovasculares/complicaciones , Muerte Súbita Cardíaca/prevención & control , Ejercicio Físico , Deportes , Adolescente , Adulto , Anciano , Estudios de Casos y Controles , Niño , Muerte Súbita Cardíaca/etiología , Femenino , Conocimientos, Actitudes y Práctica en Salud , Humanos , Masculino , Persona de Mediana Edad , Factores de Riesgo , Fumar/efectos adversos , Encuestas y Cuestionarios , Adulto Joven
10.
Curr Med Res Opin ; 24(4): 1101-14, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18328120

RESUMEN

OBJECTIVES: The objective of this study was to evaluate the effects of losartan +/- hydrochlorothiazide (HCTZ) versus placebo in obese patients with systolic and diastolic hypertension. RESEARCH DESIGN AND METHODS: Randomized patients (n = 261) were non-diabetic with systolic blood pressure (SBP) > or = 140 and < or = 180 mmHg and diastolic BP (DBP) > or = 95 and < or = 115 mmHg, body mass index > 30 kg/m(2), and waist circumference > 40 (males)/> 35 (females) inches. Patients were randomized to placebo or a forced titration of losartan 50 mg titrated at 4-week intervals to losartan 100 mg, losartan 100 mg/HCTZ 12.5 mg, and losartan 100 mg/HCTZ 25 mg. Primary efficacy measurements were change from baseline in SBP and DBP at 12 weeks. Secondary measurements were change from baseline in BPs at 8 and 16 weeks, percent responders at 12 and 16 weeks, and safety/tolerability. Post-hoc analyses were BP at 4 weeks and achievement of controlled BP (SBP < 140 and/or DBP < 90 mmHg) at 12 and 16 weeks. RESULTS: Losartan 50 mg reduced BP from 151.6/99.2 mmHg at baseline to 140.1/89.8 mmHg at week 4 (post hoc), 139.5/89.6 mmHg with losartan 100 mg at week 8 (secondary), 134.3/85.9 mmHg with losartan 100 mg/HCTZ 12.5 mg at week 12 (primary), and 132.1/84.9 mmHg with losartan 100 mg/HCTZ 50 mg at week 16 (secondary) (all p < 0.05). Rates of clinical adverse experiences were similar between treatment groups. A limitation of these analyses is the relatively rapid rate of study drug titration, which may not have allowed for the evaluation of the full treatment effect at each titration step. CONCLUSIONS: We conclude that losartan alone or in combination with HCTZ was generally well tolerated and effective in the treatment of elevated systolic and diastolic BP in obese patients with hypertension.


Asunto(s)
Antihipertensivos/uso terapéutico , Hidroclorotiazida/uso terapéutico , Hipertensión/tratamiento farmacológico , Losartán/uso terapéutico , Obesidad/fisiopatología , Adulto , Anciano , Antihipertensivos/efectos adversos , Presión Sanguínea/efectos de los fármacos , Método Doble Ciego , Quimioterapia Combinada , Femenino , Humanos , Hidroclorotiazida/efectos adversos , Hipertensión/complicaciones , Hipertensión/fisiopatología , Losartán/efectos adversos , Masculino , Persona de Mediana Edad , Obesidad/complicaciones , Factores de Tiempo , Resultado del Tratamiento
11.
Tissue Antigens ; 68(1): 62-5, 2006 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16774541

RESUMEN

The polymorphic minor histocompatibility antigen HA-1 induces powerful T-cell alloreactivities with important consequences for graft-vs-tumor activity and development of graft-vs-host disease in patients after human leukocyte antigen-matched stem-cell transplantation (SCT). In view of possible translational animal studies, we analyzed the evolutionary conservation of the diallelic HA-1 locus in four mammalian species. Our results show that rodents do not encode the HA-1(H) allele, neither show polymorphism in this position on the HA-1 gene. Contrariwise, the HA-1(H) allele is present in non-human primate species and dogs. Interestingly, both the HA-1(H) T-cell epitope and its non-immunogenic counterpart HA-1(R) are present in the latter species. Thus, the HA-1 allelic polymorphism is conserved in evolution in primates and dogs.


Asunto(s)
Alelos , Evolución Molecular , Macaca mulatta/genética , Antígenos de Histocompatibilidad Menor/genética , Sitios Menores de Histocompatibilidad , Pan troglodytes/genética , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Secuencia Conservada , Perros , Heterocigoto , Homocigoto , Antígenos de Histocompatibilidad Menor/química , Datos de Secuencia Molecular , Oligopéptidos , Ratas
12.
Heredity (Edinb) ; 97(1): 27-32, 2006 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16685282

RESUMEN

We report the identification of male-killing Spiroplasma in a wild-caught female Drosophila melanogaster from Uganda, the first such infection to be found in this species outside of South America. Among 38 female flies collected from Namulonge, Uganda in April, 2005, one produced a total of 41 female offspring but no males. PCR testing of subsequent generations revealed that females retaining Spiroplasma infection continued to produce a large excess of female progeny, while females that had lost Spiroplasma produced offspring with normal sex ratios. Consistent with earlier work, we find that male-killing and transmission efficiency appear to increase with female age, and we note that males born in sex ratio broods display much lower survivorship than their female siblings. DNA sequence comparisons at three loci suggest that this Spiroplasma strain is closely related to the male-killing strain previously found to infect D. melanogaster in Brazil, although part of one locus appears to show a recombinant history. Implications for the origin and history of male-killing Spiroplasma in D. melanogaster are discussed.


Asunto(s)
Drosophila melanogaster/genética , Drosophila melanogaster/microbiología , Spiroplasma/genética , Envejecimiento , Migración Animal , Animales , Drosophila melanogaster/fisiología , Femenino , Masculino , Reproducción , Razón de Masculinidad , Spiroplasma/aislamiento & purificación , Spiroplasma/fisiología , Simbiosis , Uganda , Wolbachia/genética , Wolbachia/aislamiento & purificación , Wolbachia/fisiología
13.
Tissue Antigens ; 59(4): 304-7, 2002 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-12135429

RESUMEN

The hematopoietic system restricted minor Histocompatibility antigen (mHag), HA-2, is encoded by the novel human class I Myosin gene, MYO1G, located on the short arm of chromosome 7. The HA-2 encoding region is di-allelic and comprises the HLA-A2 restricted T cell epitope YIGEVLVSV (HA-2V) and its allelic counterpart YIGEVLVSM (HA-2M). We designed a sequence specific PCR (SSP) for both HA-2 alleles. The HA-2 genomic typing results were compared with the HA-2 CTL phenotyping in three families and revealed exact correlation. The mHag HA-2 SSP can be incorporated in DNA based typing protocols.


Asunto(s)
Cromosomas Humanos Par 7 , Antígenos de Histocompatibilidad Menor/genética , Miosinas/genética , Reacción en Cadena de la Polimerasa/métodos , Alelos , Femenino , Humanos , Masculino , Datos de Secuencia Molecular , Linaje , Trasplante de Células Madre
14.
J Immunol ; 167(6): 3223-30, 2001 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-11544309

RESUMEN

Human minor histocompatibility Ags (mHag) present significant barriers to successful bone marrow transplantation. However, the structure of human mHag and the basis for antigenic disparities are still largely unknown. Here we report the identification of the gene encoding the human mHag HA-2 as a previously unknown member of the class I myosin family, which we have designated MYO1G. The gene is located on the short arm of chromosome 7. Expression of this gene is limited to cells of hemopoietic origin, in keeping with the previously defined tissue expression of the HA-2 Ag. RT-PCR amplification of MYO1G from different individuals led to the identification of two genetic variants, designated MYO1G(V) and MYO1G(M). The former encodes the peptide sequence previously shown to be the HA-2 epitope (YIGEVLVSV), whereas the latter shows a single amino acid change in this peptide (YIGEVLVSM). This change has only a modest effect on peptide binding to the class I MHC-restricted element HLA-A*0201, and a minimal impact on recognition by T cells when added exogenously to target cells. Nonetheless, as detected using either T cells or mass spectrometry, this amino acid change results in a failure of the latter peptide to be presented at the surface of cells that express MYO1G(M) endogenously. These studies have thus identified a new mHag-encoding gene, and thereby provide additional information about both the genetic origins of human mHag as well as the underlying basis of an Ag-positive vs Ag-negative state.


Asunto(s)
Cromosomas Humanos Par 7/genética , Genes , Antígenos de Histocompatibilidad Menor/genética , Familia de Multigenes , Miosinas/genética , Proteínas de Neoplasias/genética , Alelos , Sustitución de Aminoácidos , Presentación de Antígeno , Epítopos/genética , Exones/genética , Análisis de Fourier , Variación Genética , Antígenos HLA-A/metabolismo , Humanos , Hibridación Fluorescente in Situ , Linfocitos/metabolismo , Antígenos de Histocompatibilidad Menor/inmunología , Células Mieloides/metabolismo , Miosinas/inmunología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Homología de Secuencia de Aminoácido , Linfocitos T/inmunología
15.
J Hum Hypertens ; 15(7): 495-8, 2001 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-11464260

RESUMEN

OBJECTIVE: To compare the efficacy, tolerability, and safety of once-daily therapy with amlodipine 5 mg/benazepril 10 mg vs amlodipine 5 mg, benazepril 10 mg, and placebo. DESIGN: Randomised, double-blind, placebo-controlled, parallel-group, multicentre trial. SETTING: Twenty-two clinical centres, including private practice groups and academic research clinics. PATIENTS: A total of 530 patients between 21 and 80 years of age with essential hypertension were screened for the study, and 454 were randomised to treatment with amlodipine 5 mg/benazepril 10 mg, amlodipine 5 mg, benazepril 10 mg, or placebo for 8 weeks. RESULTS: Amlodipine 5 mg/benazepril 10 mg produced greater reductions from baseline in sitting diastolic blood pressure than amlodipine 5 mg (P < 0.03), benazepril 10 mg (P < 0.001), and placebo (P < 0.001). The response rate in the amlodipine 5-mg/benazepril 10-mg treatment group (66.4%) was better than that observed in the amlodipine 5-mg (50.0% P < 0.02), benazepril 10-mg (38.3% P < 0.001), and placebo (24.4% P < 0.001) groups. There was no significant difference in heart rate among the four groups. The incidence of oedema in the amlodipine 5-mg/benazepril 10-mg (1.7%) group was somewhat less than that in the amlodipine 5-mg (4.5%) group. CONCLUSIONS: Therapy with amlodipine 5 mg/benazepril 10 mg was well tolerated and was superior to amlodipine 5 mg, benazepril 10 mg, and placebo in reducing sitting diastolic blood pressure in patients with essential hypertension.


Asunto(s)
Amlodipino/administración & dosificación , Antihipertensivos/administración & dosificación , Benzazepinas/administración & dosificación , Hipertensión/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Método Doble Ciego , Quimioterapia Combinada , Femenino , Humanos , Hipertensión/fisiopatología , Masculino , Persona de Mediana Edad , Resultado del Tratamiento
16.
Invest Clin ; 42(2): 87-106, 2001 Jun.
Artículo en Español | MEDLINE | ID: mdl-11416982

RESUMEN

A descriptive and cross sectional study was conducted to determine whether hepatic function changes in workers occupationally exposed to a mixture of organic solvents, were due to the exposure or confusing factors. A non random sample of 77 workers, operators and supervisors of the Olefin Plant I and II of a petrochemical industry in Maracaibo, Venezuela, was used. Their mean age was 29 +/- 7 years, and had at least one year of exposure to the solvents. This sample was compared with a group of employees of the administrative offices or control panel workers, with a mean age of 36 +/- 8 year and with similar anthropometric characteristics. Workers with a known history of liver disease, blood transfusions and diabetes mellitus were excluded of the study. In addition to a complete occupational disease medical history and a physical examination, serum samples were obtained to determine the activity of the aspartato aminotransferase (AST), alanin aminotransferase (ALT), gamma glutamiltransferase (GGT), alkaline phosphatase (AF), the concentration of the total bile acids (BAS), the surface antigen of hepatitis B(HbsAg) and the hepatitis A virus antibodies: AntiHAV-IgG and the AntiHAV-IgM. An urine sample was taken and analyzed by standard methodology to determine urinary phenols. The air concentrations of benzene, ethylbenzene, toluene and xylene were analyzed by gas chromathography. The serum activities of the liver enzymes, the concentration of bile acids and urinary phenols were not influenced by the exposure to the solvents. The increase of the activity of GGT was associated with obesity and alcohol consumption. The antibodies of the surface antigen of hepatitis A-IgM were normal in both groups and the antibodies for the antigen of hepatitis A-IgG presented a prevalence of 6% in the exposed group and 9% in the non exposed not being associated with liver abnormalities. The individual air concentrations of the solvents were below the environmentally permissible concentrations, except one sample of benzene (1, 14 ppm) that was over the allowed limit. The total maximum concentration of the mixture of organic solvents, resulting of the sum of fractions of each organic solvent, was within the allowed limits. In conclusion, obesity and alcohol consumption, and not the occupational factors, seem to be responsible for the alteration in GGT in workers of these Olefin Plants.


Asunto(s)
Benceno/efectos adversos , Industria Procesadora y de Extracción , Hígado/efectos de los fármacos , Exposición Profesional/efectos adversos , Fenoles/orina , Adulto , Alanina Transaminasa/sangre , Fosfatasa Alcalina/sangre , Aspartato Aminotransferasas/sangre , Biomarcadores/orina , Estudios Transversales , Monitoreo del Ambiente/métodos , Humanos , Pruebas de Función Hepática , Masculino , Persona de Mediana Edad , Exposición Profesional/análisis , Solventes/efectos adversos , Venezuela
17.
Am J Cardiol ; 87(6): 727-31, 2001 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-11249891

RESUMEN

The comparative antihypertensive efficacy and tolerability of the angiotensin II receptor blocker candesartan cilexetil and the calcium channel blocker amlodipine were evaluated in an 8-week, multicenter, double-blind, randomized, parallel-group, forced-titration study in 251 adult patients (45% women, 16% black) with mild hypertension (stage 1). Following a 4- to 5-week placebo run-in period, patients with sitting diastolic blood pressure (BP) of 90 to 99 mm Hg received candesartan cilexetil 16 mg (n = 123) or amlodipine 5 mg (n = 128) once daily. After 4 weeks of double-blind treatment, patients were uptitrated to candesartan cilexetil 32 mg or amlodipine 10 mg once daily. There were no significant differences between the candesartan cilexetil and amlodipine regimens for reducing BP; mean systolic BP/diastolic BP reductions were -15.2/-10.2 mm Hg versus -15.4/-11.3 mm Hg, respectively (p = 0.88/0.25). Overall, 79% of patients on candesartan cilexetil and 87% of those on amlodipine were controlled (diastolic BP <90 mm Hg). A total of 3.3% of patients on candesartan cilexetil discontinued treatment, compared with 9.4% of patients on amlodipine, including 2.4% versus 4.7% for adverse events and 0% versus 1.6% for peripheral edema, respectively. Peripheral edema, the prespecified primary tolerability end point, occurred with significantly greater frequency in patients on amlodipine (22.1%; mild 8.7%, moderate 11.8%, severe 1.6%) versus patients on candesartan cilexetil (8.9%; mild 8.1%, moderate 0.8%) (p = 0.005). Candesartan cilexetil and amlodipine are both highly effective in controlling BP in patients with mild hypertension. Candesartan cilexetil offers a significant tolerability advantage with respect to less risk of developing peripheral edema.


Asunto(s)
Amlodipino/uso terapéutico , Antihipertensivos/uso terapéutico , Bencimidazoles/uso terapéutico , Compuestos de Bifenilo/uso terapéutico , Bloqueadores de los Canales de Calcio/uso terapéutico , Hipertensión/tratamiento farmacológico , Profármacos/uso terapéutico , Tetrazoles , Amlodipino/efectos adversos , Antihipertensivos/efectos adversos , Bencimidazoles/efectos adversos , Compuestos de Bifenilo/efectos adversos , Presión Sanguínea/efectos de los fármacos , Bloqueadores de los Canales de Calcio/efectos adversos , Método Doble Ciego , Edema/inducido químicamente , Femenino , Humanos , Hipertensión/fisiopatología , Masculino , Persona de Mediana Edad , Satisfacción del Paciente , Profármacos/efectos adversos , Estudios Prospectivos , Resultado del Tratamiento
18.
Int Urol Nephrol ; 33(3): 407-12, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-12230262

RESUMEN

Alpha1-adrenoceptor antagonists have been shown to provide effective relief from symptoms of benign prostatic hyperplasia (BPH) with attendant improvements in quality of life. Although the alpha1A-adrenoceptor subtype predominates over other subtypes of alpha1 adrenoceptors in the prostate gland, there is no evidence that a subselective alpha-adrenoceptor antagonist provides a clinical advantage over a selective alpha1-adrenoceptor antagonist in the treatment of patients with BPH. The pharmacokinetic profiles of alpha1A-adrenoceptor antagonists and their documented penetration of the blood-brain barrier (CNS adverse effects) preclude a clinical benefit of subselective alpha-adrenoceptor blockers over selective alpha1 blockers.


Asunto(s)
Antagonistas Adrenérgicos alfa/uso terapéutico , Hiperplasia Prostática/tratamiento farmacológico , Quinazolinas/uso terapéutico , Receptores Adrenérgicos alfa 1/clasificación , Antagonistas Adrenérgicos alfa/farmacocinética , Anciano , Anciano de 80 o más Años , Barrera Hematoencefálica , Doxazosina/farmacocinética , Doxazosina/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Quinazolinas/farmacocinética , Receptores Adrenérgicos alfa 1/metabolismo
19.
Invest Clin ; 42(4): 225-34, 2001 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11787267

RESUMEN

In 1993 a total of 356 accidents with injuries occurred in workers of 26 companies of oil and gas extraction in the eastern coast of Maracaibo Lake in Venezuela. 288 of them worked in drilling tasks. With the purpose of analyzing the factors that are associated with the drilling activities, the data base of the Venezuela Institute of Social Security, was reviewed. Only the first two digits of the Standard Industrial Classification were used in this study. For preventive reasons this study focused on six variables: unsafe condition or mechanical cause, insecure action, external agent, type of the accident, part of the body injured and the nature of the injury. The following results were obtained: the frequency rate was 222.3 by 1,000, most of them were minor and were caused by not paying attention when walking on or around labor areas (37%), thus favoring being struck by lifting machines (14%); also 62% occurred in non-classified conditions that injured the upper and lower extremities (48% and 24%) producing contusions and crushing (39%). In conclusion, most injuries occurring in the activity of oil and gas extraction are due to factors controllable with preventive strategies.


Asunto(s)
Accidentes de Trabajo/estadística & datos numéricos , Industria Procesadora y de Extracción , Petróleo , Accidentes de Trabajo/prevención & control , Adulto , Industria Procesadora y de Extracción/estadística & datos numéricos , Humanos , Salud Laboral , Venezuela/epidemiología
20.
Neurosurgery ; 46(3): 721-8; discussion 728-9, 2000 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-10719869

RESUMEN

This concerns my activities as a neurosurgeon in the European Theater of Operations and the North African, Tunisian campaign, during World War II. Action during the Battle of the Bulge came later. Our mobile tent hospital, the 9th Evacuation Hospital, was similar to that depicted in the television show M*A*S*H. To lend flavor to these comments, I have referred to medical and surgical matters in other units as well as our own, mentioned global aspects of the war, and included vignettes of life off-duty. The story begins after induction into the Army Medical Corps as a volunteer in July 1942 and ends with honorable discharge in April 1946.


Asunto(s)
Medicina Militar , Neurocirugia , Guerra , África del Norte , Europa (Continente) , Historia del Siglo XX , Humanos , Personal Militar , Estados Unidos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...